Clinical ophthalmology (Auckland, N.Z.)最新文献

{"title":"The Multifocal Pathway: A Pilot Study of a Trainee-Led Multifocal Intraocular Lens Protocol in a Tertiary Referral Hospital in Australia.","authors":"Lauren Sartor, Christopher Ze Qian Go, Cheng F Kong, Season T W Yeung, Andrew White, Chameen Samarawickrama","doi":"10.2147/OPTH.S484884","DOIUrl":"10.2147/OPTH.S484884","url":null,"abstract":"<p><strong>Purpose: </strong>To develop a selection pathway to facilitate the use of multifocal intraocular lenses (mfIOLs) in cataract surgery in a public hospital setting.</p><p><strong>Methods: </strong>A single-surgeon prospective cohort study in an Australian tertiary referral public hospital was conducted. A mfIOL selection pathway was designed and assessed. Outcomes measured included unaided distance (UDVA), intermediate (UIVA) and near visual acuity (UNVA), dysphotopsia, spectacle dependence and satisfaction. Patient-reported outcome measures (PROMs) were assessed using Catquest-9SF (CQ) and Near Visual Acuity Questionnaire (NAVQ). A cost-analysis was performed.</p><p><strong>Results: </strong>Fifty-four eyes from 27 patients underwent cataract surgery with mfIOL implantation. The monocular UDVA (mean ± standard deviation) was 0.05 ± 0.12 logMAR; UIVA 0.19 ± 0.05 logMAR; UNVA 0.28 ± 0.14 logMAR; 87% and 98% of eyes achieved within 0.5D and 1.0D of target refraction respectively. Spectacle independence was 85% at distance, 81% at intermediate, 59% at near vision. High satisfaction was reported with CQ (>85%) and NAVQ (100%). The cost difference between bilateral monofocal and mfIOLs is comparable to a pair of spectacles. Projected annual cost to the health system for a 5%-10% eligibility rate is 1.1-2.3 million Australian dollars.</p><p><strong>Conclusion: </strong>The selection pathway presented overcomes the challenges in patient selection inherent to a public hospital setting and was implemented by a senior trainee with excellent vision and PROMs. The pathway ensures the cost-effectiveness of mfOL implantation. There are several funding models that can be applied to support equitable access and improved visual outcomes with mfIOLs within the government funded health system.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3693-3706"},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corneal Epithelial Thickness Correlation with Dry Eye Symptom Severity: A Cross-Sectional Study [Response to Letter].","authors":"Bruno Barbosa Ribeiro, João Heitor Marques, Pedro Manuel Baptista, Paulo J M Sousa, Saúl Pires, Pedro Menéres, Irene Barbosa","doi":"10.2147/OPTH.S509241","DOIUrl":"10.2147/OPTH.S509241","url":null,"abstract":"","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3691-3692"},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Real-World Healthcare Resource Utilization, Healthcare Costs, and Injurious Falls Among Elderly Patients with Geographic Atrophy\" [Letter].","authors":"Ahmad Yani Noor, Nurrul Ainy, Harinto Nur Seha","doi":"10.2147/OPTH.S508505","DOIUrl":"10.2147/OPTH.S508505","url":null,"abstract":"","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3707-3708"},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brolucizumab versus Aflibercept in Patients with Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials.","authors":"Leonardo B Justino, Gustavo B Justino, Fabrissio P Graffunder, William W Binotti, Ali Khodor, Jonathan T Caranfa","doi":"10.2147/OPTH.S487055","DOIUrl":"10.2147/OPTH.S487055","url":null,"abstract":"<p><strong>Purpose: </strong>To assess efficacy and safety of brolucizumab versus aflibercept in patients with diabetic macular edema (DME).</p><p><strong>Patients and methods: </strong>We performed a systematic review and meta-analysis with trial sequential analysis (TSA). We searched Embase, Cochrane Central Register of Controlled Trials and PubMed databases from inception to February 16, 2024 for randomized controlled trials (RCTs) comparing brolucizumab with aflibercept in patients with DME and reporting any of the visual, anatomical and safety outcomes of interest. We conducted a TSA of safety outcomes to assess the risk of statistical errors.</p><p><strong>Results: </strong>1253 patients (1253 eyes) from 3 RCTs were included, of whom 57% received brolucizumab and 43% received aflibercept. Mean follow-up ranged from 52 to 100 weeks. Brolucizumab was non-inferior to aflibercept when comparing the mean change of best-corrected visual acuity from baseline (least squares mean difference [LSMD] 0.29; 95% confidence interval [CI] -1.37 to 1.95; p = 0.73). Change in central subfield thickness was significantly greater in the brolucizumab group compared with aflibercept (LSMD -24.5 μm; 95% CI -48.2 to -0.7 μm; p < 0.05). Incidence of adverse events of special interest (AESIs) (risk ratio [RR] 1.7; p = 0.08) and incidence of ≥1 ocular adverse events (AEs) (RR 0.95; p = 0.45) were not significantly different between groups.</p><p><strong>Conclusion: </strong>Brolucizumab was non-inferior in functional outcomes and was superior to aflibercept in anatomical parameters. Ocular AEs and AESIs were numerically low and not statistically significant. Our findings underscore the importance of new RCTs powered to assess safety outcomes in order to suggest brolucizumab as an alternative to the treatment of DME.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3679-3690"},"PeriodicalIF":0.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Affordable, Portable International Visionkeys System for Visual Acuity and Stereopsis.","authors":"Lily A Karlberg, Taylor R Sweeney, Robert W Arnold","doi":"10.2147/OPTH.S494457","DOIUrl":"10.2147/OPTH.S494457","url":null,"abstract":"<p><strong>Background: </strong>A new, portable computerized distance vision testing (screen plus remote) system called VisionKeys has been developed by the missions equipment developer EyeMobil so we validated it compared to conventional research testing devices.</p><p><strong>Methods: </strong>Using a standardized protocol of surround HOTV optotype presentation, the VisionKeys was compared to M&S for patched monocular distance visual acuity. A different VisionKeys function with anaglyph spectacle distance stereopsis was compared to near stereo on Titmus circles with Polaroid goggles and PDI Check on an autostereoscopic screen. Raw scores were converted to logarithm and compared with non-parametric and Bland Altman tests.</p><p><strong>Results: </strong>We recruited 145 ethnically diverse patients with range of acuity -0.4 to 2.6 (NLP) logMAR from a pediatric eye and adult strabismus practice showing median logMAR acuity of 0.0 with VisionKeys significantly finer resolution than 0.1 for M&S (Mann-Whitney z=2.6, p=0.01, n=290). VisionKeys acuity correlated very well with M&S and children under age 7 scored coarser than teens and young adults. Median distance log arc seconds stereo on VisionKeys (2.00) differed from near Titmus circles (1.78) and PDI Check (1.89, Kruskal-Wallis X2(2)=9.8, p=0.007) however they all correlated well by Bland Altman.</p><p><strong>Conclusion: </strong>The new, portable VisionKeys system gives valid distance visual acuity with slightly finer estimate compared to M&S and the distance stereo compared well with near Titmus and PDI Check. As such, it should be valuable for testing children and adults in remote locations.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3667-3677"},"PeriodicalIF":0.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of Workload Associated with Anti-VEGF Treatments for AMD, DME, RVO and mCNV in Hospital District of Southwest Finland.","authors":"Hanna Heloterä, Anna-Mari Viita, Juha Laine","doi":"10.2147/OPTH.S479816","DOIUrl":"10.2147/OPTH.S479816","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of vision-threatening diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME), is likely to increase in developed countries owing to an aging population, rising life expectancy, and unfavorable lifestyle changes. Increases in the burden of vision-threatening diseases pose a challenge to the healthcare system. After the emergence of intravitreal anti-VEGF inhibitors, treatment options for neovascular AMD (nAMD), DME, retinal vein occlusion (RVO) and myopic choroidal neovascularization (myopic CNV) have increased. As this change in treatment practices has occurred over the last two decades, it is important to demonstrate changes in patient numbers and administered treatments to provide solutions for handling the workload and productivity in ophthalmology departments. In addition, the registry data landscape has evolved in Finland in recent years. Thus, understanding the possibilities and limitations of ophthalmology registries and patient information systems is required.</p><p><strong>Methods: </strong>This study involved the secondary use of retrospectively registered data from the data warehouse of the Hospital District of Southwest Finland. Our goal was to explore how the workload of ophthalmology departments caused by intravitreal injections has evolved from 2015 to 2022.</p><p><strong>Results: </strong>The ophthalmology department workload increased significantly during our observation period as the total number of patients receiving intravitreal treatments for nAMD, DME, RVO, and myopic CNV increased 199.6% from 2015 to 2021. In addition, the total number of administered anti-VEGF injections increased during our observation period, but the increase rate began to subside (2019-2020: increase 23.7%, 2020-2021: increase 10.3%, 2021-2022: increase 6.7%).</p><p><strong>Conclusion: </strong>Supporting the utilization of registry data is essential in evidence-based discussions evolving workload in healthcare. However, it is important to understand the limitations and the quality of the registries. Our study contributes to better understanding the Finnish registry perspective, and it demonstrates the increase in workload in ophthalmology departments caused by intravitreal injections.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3645-3655"},"PeriodicalIF":0.0,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11640760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Phacoemulsification and 360-Degree Suture Trabeculotomy Ab Externo in Primary Chronic Angle Closure Glaucoma: A Modified Technique.","authors":"Abdelhamid Shaker Elhofi, Hany Ahmed Helaly, Rania Eldakhs","doi":"10.2147/OPTH.S480485","DOIUrl":"10.2147/OPTH.S480485","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the outcome of combined phacoemulsification and 360-degree suture trabeculotomy ab externo in chronic angle closure glaucoma using a modified technique.</p><p><strong>Methods: </strong>This is a retrospective clinical study that included 60 eyes of 60 patients who had undergone combined phacoemulsification and 360-degree suture trabeculotomy ab externo for the treatment of primary chronic angle closure glaucoma. The patients were divided into two groups. The first group (ab externo group) and the second group (modified ab externo group). Data were collected from the records and the final follow-up visit including age, sex, intraocular pressure (IOP), number of antiglaucoma medications, presence of complications, corrected distant visual acuity, and need for another intervention. All the included patients completed at least 12 months follow-up.</p><p><strong>Results: </strong>The ab externo group included 30 patients and the modified ab externo group included 30 patients. The postoperative IOP was reduced in both groups significantly from the preoperative levels. The percent of reduction was around 60% for both groups (59.5% for the ab externo group and 59.3% for the modified ab externo group). There was statistically significant reduction in the mean amount of required topical medications after the intervention for both groups (p = 0.001). Most of the complications were not serious. Around 90% of the cases in both groups had mild degree of grade 1 hyphema.</p><p><strong>Conclusion: </strong>Both ab externo 360 degree suture trabeculotomy and its modified technique with ab interno pulling of the suture when combined with phacoemulsification are safe and provide adequate decrease in the intraocular pressure. Modified technique of ab interno pulling of the prolene suture might be more gentle procedure with less severe hyphema and lower chance of rupture of trabeculo-Descemet's membrane.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3657-3666"},"PeriodicalIF":0.0,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translation, Evaluation and Validation of the Adult Strabismus -20 (AS-20) Questionnaire in Swedish.","authors":"Lena Havstam Johansson, Anna Levinsson, Sara M Flodin","doi":"10.2147/OPTH.S477032","DOIUrl":"10.2147/OPTH.S477032","url":null,"abstract":"<p><strong>Purpose: </strong>To translate and validate the Adult Strabismus 20 (AS-20) questionnaire, a health-related quality of life questionnaire specifically devised for patients with strabismus.</p><p><strong>Methods: </strong>The AS-20 was translated in accordance with the principles of good practice for the translation and cultural adaptation process for patient-related outcomes (PRO) according to the methodology recommended by the International Society for Pharmacoeconomics and Outcome Research (ISPOR). The translation, evaluation, and validation were performed in several steps. The study used both qualitative and quantitative methods and engaged 31 final-year orthoptic students in workshops, as well as 19 experts (experienced clinical orthoptists), 17 laymen (members of the public), and 17 patients from national eye clinics. The final translated questionnaire was tested for reliability and validity in 68 adults with strabismus by internal consistency using Cronbach´s alpha and content and construct validity using the Rasch analysis.</p><p><strong>Results: </strong>The Swedish AS-20 showed a high level of internal consistency. Cronbach´s alpha was 0.95 for the psychosocial subscale and 0.92 for the functional subscale. However, the Rasch analysis indicated that both items and responses should be condensed to achieve content and construct validity.</p><p><strong>Conclusion: </strong>The thorough translation and evaluation process resulted in a validated AS-20 questionnaire for use in the Swedish language, and shows reliability as an instrument to measure health-related quality of life (HRQoL) in adults with strabismus in a clinical setting.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3615-3625"},"PeriodicalIF":0.0,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Prognostic Factors of Patients with Intraocular Foreign Bodies from a Tertiary Eye Center in North China.","authors":"Xiaoli Xing, Fang Liu, Yan Qi, Jun Li, Bin Yu, Lei Wan","doi":"10.2147/OPTH.S492986","DOIUrl":"10.2147/OPTH.S492986","url":null,"abstract":"<p><strong>Background: </strong>This study aims to describe the epidemiology and clinical features of patients with intraocular foreign bodies (IOFBs) and analyze the prognostic factors influencing final vision.</p><p><strong>Methods: </strong>We retrospectively reviewed medical records of patients with IOFBs admitted to Qingdao Eye Hospital of Shandong First Medical University between January 1, 2014, and December 31, 2021. Inclusion criteria involved complete clinical data details of patients diagnosed with intraocular foreign bodies in our hospital who were treated with concurrent surgery and based on IOFB position and characteristics, different surgical methods were employed. The minimum follow-up duration was 6 months. Exclusion criteria were foreign bodies retained in the orbit, organ failure, surgical contraindications, coagulation abnormalities, autoimmune diseases, history of ocular surgery, and ocular space-occupying lesions. Based on IOFB position and characteristics, different surgical methods were employed. Multivariate logistic regression analysis was performed to predict independent factors influencing final visual acuity after IOFBs.</p><p><strong>Results: </strong>This study analyzed 159 patients (159 eyes) with IOFBs. Based on discharge and follow-up results, IOFB removal was performed through pars plana incision in 105 (67.9%) eyes, corneoscleral limbus incision in 24 (15.1%) eyes, and original wound in 27 (17.0%) eyes. Of these, 44 eyes underwent IOFB removal without vitrectomy, while 55 (34.6%) eyes were treated with silicone oil. Post-vitrectomy, three cases showed secondary macular membrane, five cases exhibited retinal detachment, and enucleation was necessary in three cases. The final best corrected visual acuity (BCVA, logMAR) was 1.06 ±0.88, significantly better than preoperative visual acuity of 1.65 ±0.87 (t = 8.21, p < 0.01). Multi-factor logistic regression analysis revealed that the length of corneal/scleral wound (OR=0.6 P < 0.05), maximum size of IOFB (OR=0.585 P < 0.05), initial presenting VA (OR=0.900 P < 0.05), and macular lesions(OR=0.400 P < 0.05) were risk factors for postoperative vision prognosis after intraocular foreign body surgery.</p><p><strong>Conclusion: </strong>In a tertiary eye center in northern China, IOFBs predominantly affected the working-age group, particularly males. Factors such as wound length, IOFB size, initial presenting VA, and macular lesions might impact the final visual outcome.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3635-3643"},"PeriodicalIF":0.0,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bio-Interventional Cyclodialysis and Allograft Scleral Reinforcement for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients: One-Year Clinical Outcomes.","authors":"Tsontcho Ianchulev, Robert N Weinreb, Ernesto A Calvo, James Lewis, Gautam Kamthan, Arsham Sheybani, Douglas J Rhee, Iqbal K Ahmed","doi":"10.2147/OPTH.S496631","DOIUrl":"10.2147/OPTH.S496631","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the one-year safety and effectiveness of bio-interventional cyclodialysis and scleral reinforcement in open-angle glaucoma (OAG) patients undergoing cataract surgery.</p><p><strong>Methods: </strong>An ab-interno approach was used to create a sectoral cyclodialysis in OAG patients who were prospectively followed in a consecutive case series. Subsequent visco-cycloplasty with scleral reinforcement using homologous minimally modified allograft scaffold was completed to maintain patency of the cyclodialysis reservoir and increase uveoscleral outflow. Outcomes were mean medicated IOP and mean number of IOP-lowering medications. Safety outcomes were adverse events (AEs) and best-corrected visual acuity (BCVA) changes.</p><p><strong>Results: </strong>Successful cyclodialysis and allograft bio-scaffold reinforcement was achieved in 117 eyes. There was minimal intraoperatie bleeding and few post-operative adverse events. At baseline, mean BCVA was 0.48 (95% CI: 0.42‒0.54; 20/40 Snellen) and mean ± SD medicated IOP was 20.2 ± 6.0 mmHg on 1.4 ± 1.3 IOP-lowering medications. At 12 months, there was a 27.1% reduction from baseline mean medicated IOP. In eyes with medicated baseline IOP > 21 mmHg (n = 45), there was a 39.7% paired IOP reduction at 12 months with a concurrent reduction in the mean number of IOP lowering medications to 0.8 ± 0.9 which were statistically significant (p < 0.01). For all eyes, 81.9% achieved a medicated IOP ≤ 18 mmHg with no increase in medications at 12 months. To achieve target IOP control, secondary glaucoma surgery was performed in 3.2% of the cases.</p><p><strong>Conclusion: </strong>IOP lowering through uveoscleral outflow enhancement can be achieved by means of a bio-interventional cyclodialysis procedure with allograft scleral reinforcement.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3605-3614"},"PeriodicalIF":0.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}